Zobrazeno 1 - 10
of 241
pro vyhledávání: '"Jeff P. Sharman"'
Autor:
Linlin Xu, Mazyar Shadman, Ian W. Flinn, Moshe Y. Levy, Ryan Porter, John M. Burke, Syed F. Zafar, Jennifer L. Cultrera, Jamal Misleh, Edwin C. Kingsley, Habte A. Yimer, Benjamin Freeman, Arvind Chaudhry, Praveen K. Tumula, Mitul D. Gandhi, Rocco Crescenzo, Kunthel By, Aileen Cohen, Dih-Yih Chen, Adam Idoine, Sudhir Manda, Jeff P. Sharman, Vanitha Ramakrishnan
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/1c2ee5ac31c545ed8f557348df39cf33
Autor:
Anthony Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Yi Han, Xiaowei Zhang, Lindsey Roeker, Nicola Wallis, Jennifer C. Stern, Eric Hedrick, Jane Huang, Jeff P. Sharman
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 135-144 (2023)
Abstract Ibrutinib, a Bruton's tyrosine kinase inhibitor, is often used as first‐line (1L) treatment of chronic lymphocytic leukaemia (CLL); however, it is associated with an increased risk for cardiovascular adverse events (CVAEs). This real‐wor
Externí odkaz:
https://doaj.org/article/6e2bc983c365456688227cc361fb4cc9
Autor:
Miguel A. Canales, Thomas A. Buchholz, Jaisson A.P. Bortolini, Laura M. Fogliatto, Takayuki Ishikawa, Koji Izutsu, Antonio Salar, Jeff P. Sharman, Dirk Klingbiel, Sunny Pokala, Ekaterina Vorozheikina, Peter Trask, Joana Parreira, Kai Hübel
Publikováno v:
HemaSphere, Vol 7, Iss 4, p e860 (2023)
Externí odkaz:
https://doaj.org/article/d7f09369c3394dc7bc1595f8a3af8bcc
Autor:
Anthony R. Mato, Boxiong Tang, Soraya Azmi, Keri Yang, Xiaojuan Zhang, Jennifer C. Stern, Eric Hedrick, Jane Huang, Jeff P. Sharman
Publikováno v:
Haematologica, Vol 107, Iss 11 (2022)
Among patients with chronic lymphocytic leukemia (CLL) with deletion 17p (del[17p]), evidence from clinical trials for the effectiveness of single-agent ibrutinib as first-line therapy is limited. This retrospective analysis compared real-world clini
Externí odkaz:
https://doaj.org/article/eaa4a98279524f35a4baac869f3a349a
Autor:
Jeff P. Sharman, Kim Cocks, Chadi Nabhan, Nicole Lamanna, Neil E. Kay, David L. Grinblatt, Christopher R. Flowers, Matthew S. Davids, Pavel Kiselev, Arlene S. Swern, Kristen Sullivan, Mecide M. Gharibo, E. Dawn Flick, Andrew Trigg, Anthony Mato
Publikováno v:
eJHaem, Vol 1, Iss 1, Pp 188-198 (2020)
Abstract Health‐related quality of life (HRQoL) in patients with chronic lymphocytic leukemia (CLL) is important in guiding treatment decisions. However, the impact of CLL treatment initiation on HRQoL is unclear. We assessed HRQoL using the FACT
Externí odkaz:
https://doaj.org/article/34c06b8e749f4507ab23a49de144c417
Autor:
John N. Allan, Javier Pinilla-Ibarz, Douglas E. Gladstone, Krish Patel, Jeff P. Sharman, William G. Wierda, Michael Y. Choi, Susan M. O’Brien, Mazyar Shadman, Matthew S. Davids, John M. Pagel, Habte A. Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L. Combs, Judith A. Fox, Richard R. Furman, Jennifer R. Brown
Publikováno v:
Haematologica, Vol 107, Iss 4 (2021)
Externí odkaz:
https://doaj.org/article/2b83f0254400461d8896d202887eadb7
Autor:
Susan M. O’Brien, Jennifer R. Brown, John C. Byrd, Richard R. Furman, Paolo Ghia, Jeff P. Sharman, William G. Wierda
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Bruton tyrosine kinase (BTK) inhibitors represent an important therapeutic advancement for B cell malignancies. Ibrutinib, the first-in-class BTK inhibitor, is approved by the US FDA to treat patients with chronic lymphocytic leukemia (CLL)/small lym
Externí odkaz:
https://doaj.org/article/b1b57d9d157d496799b9fdf515094b55
Autor:
Jennifer R. Brown, John C. Byrd, Paolo Ghia, Jeff P. Sharman, Peter Hillmen, Deborah M. Stephens, Clare Sun, Wojciech Jurczak, John M. Pagel, Alessandra Ferrajoli, Priti Patel, Lin Tao, Nataliya Kuptsova-Clarkson, Javid Moslehi, Richard R. Furman
Publikováno v:
Haematologica, Vol 107, Iss 6 (2021)
Cardiovascular (CV) toxicities of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib may limit use of this effective therapy in patients with chronic lymphocytic leukemia (CLL). Acalabrutinib is a second-generation BTK inhibitor with greater BTK se
Externí odkaz:
https://doaj.org/article/539d278310f84aa3955bb4b7eb5f3b1d
Autor:
Anas Younes, John M. Burke, Bruce D. Cheson, Catherine S. Diefenbach, Silvia Ferrari, Uwe H. Hahn, Eliza A. Hawkes, Cyrus Khan, Izidore S. Lossos, Gerardo Musuraca, Monica Tani, Umberto Vitolo, Sam Yuen, Aparna Raval, Mahesh Shivhare, Tina G. Nielsen, Gila Sellam, Jeff P. Sharman
Publikováno v:
Blood Advances. 7:1488-1495
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the current standard therapy for patients with diffuse large B-cell lymphoma (DLBCL) and is curative in ∼60% of patients. Atezolizumab is a humanized immunoglobul
Autor:
Kerry A. Rogers, Philip A. Thompson, John N. Allan, Morton Coleman, Jeff P. Sharman, Bruce D. Cheson, Daniel Jones, Raquel Izumi, Melanie M. Frigault, Cheng Quah, Rakesh K. Raman, Priti Patel, Min Hui Wang, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 106, Iss 9 (2021)
B-cell receptor signalling inhibition by targeting Bruton tyrosine kinase (BTK) is effective in treating chronic lymphocytic leukemia (CLL). The BTK inhibitor ibrutinib may be intolerable for some patients. Acalabrutinib is a more selective BTK inhib
Externí odkaz:
https://doaj.org/article/1f8e5a0d250d49f8bc29eb2cbf686fb6